Skip to main content
    R

    Rani Therapeutics Holdings Inc (RANI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.56
    +0.02 (+3.54%)

    Market Cap: $60.78M

    Last updated: Nov 17, 2026 at 4:19 PM ET

    Rani Therapeutics Holdings Inc (RANI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rani Therapeutics Holdings (RANI) has a market cap of $60.78M and an enterprise value of $57.16M. Its share count is up 328.49% from a year earlier. It kept -521.20% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 5.96% below the market cap, as cash exceeds debt.

    Market Cap$60.78M
    Enterprise Value$57.16M
    Latest price (Nov 17, 2026)$0.56

    Key Dates

    The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 25, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 6.32% in the quarter ended Sep 30, 2026 and grew 162.70% a year over 2 years.

    Shares Outstanding199.01M
    Shares Change (YoY)+328.49%
    Shares Change (QoQ)+6.32%
    Share Count Growth (2Y CAGR)+162.70%

    Valuation Ratios

    Sales and book value multiples are 16.9x and 3.3x. Its year-end P/S ranged from 31.2x to 89.5x from 2023 to 2025.

    P/S Ratio16.9x
    Forward P/S9.5x
    P/B Ratio3.3x

    Valuation history and multiples

    Price Statistics

    The stock is down 70.24% over 52 weeks and trades 18.84% below its 50-day average.

    Beta (1Y)2.27
    52-Week Change-70.24%
    1-Month Change-13.98%
    3-Month Change-38.97%
    6-Month Change-36.75%
    5-Year Change-97.43%
    Total Return (1Y)-70.24%
    Total Return (3Y CAGR)-34.70%
    Total Return (5Y CAGR)-56.30%
    Max Drawdown (1Y)-73.39%
    Max Drawdown (3Y)-94.78%
    Sharpe Ratio (1Y)-1.46
    Correlation with SPY (1Y)0.38
    50-Day Average$0.69
    200-Day Average$0.89
    52-Week Range$0.50 to $1.91
    RSI (14 Days)41.5
    Average Volume (20 Days)514.57K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.26x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.26x
    Quick Ratio5.26x
    Debt / Equity0.00x
    Interest Coverage-32.92x

    Returns and Efficiency

    Return on equity is -101.01% and return on assets is -65.33% over the last 12 months.

    Return on Equity (ROE)-101.01%
    Return on Assets (ROA)-65.33%
    ROA (5Y Average)-88.58%
    Asset Turnover0.21x
    Receivables Turnover3.29x

    Scores

    RANI has an Altman Z-Score of 0.68, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score0.68
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $6.58M over the last 12 months is up 448.67% from the 12 months before.

    Revenue$6.58M
    Revenue Growth (YoY)+448.67%
    Gross Profit$6.58M
    Operating Income-$34.92M
    Pretax Income-$34.32M
    Net Income-$34.32M
    EBITDA-$33.69M
    Reported EPS (TTM)-$0.19

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 64.67% of the $52.53M in total assets.

    Cash and Equivalents$3.62M
    Total Debt$0
    Net Cash$3.62M
    Net Cash Per Share$0.02
    Working Capital$39.25M
    Shareholder Equity$33.97M
    Book Value Per Share$0.17
    Total Assets$52.53M
    Total Liabilities$11.18M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $230.00K of capital spending, operating cash flow left -$23.22M of free cash flow.

    Operating Cash Flow-$22.99M
    Capital Expenditures$230.00K
    Free Cash Flow-$23.22M
    FCF Per Share-$0.20
    Depreciation and Amortization$2.43M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -530.45%.

    Gross Margin100.00%
    Operating Margin-530.45%
    Pretax Margin-521.20%
    Net Margin-521.20%
    EBITDA Margin-511.71%
    FCF Margin-352.67%

    Growth

    Revenue Growth (5Y CAGR)+28.73%
    Book Value Per Share Growth (2Y CAGR)-32.82%
    Tangible Book Per Share Growth (2Y CAGR)-32.82%

    Revenue and profit by year

    Dividends and Yields

    RANI does not pay a dividend.

    Buyback Yield-61.23%
    Shareholder Yield-61.23%

    Peer Position

    Against 6 similar companies, RANI has the 6th highest P/S.

    P/S Ratio16.9x vs 33.3x median
    Revenue Growth (Trailing 4 Quarters, YoY)+448.67% vs -13.92% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 85.94% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+85.94%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RANI

    What is RANI's market cap?

    Rani Therapeutics Holdings has a market cap of $60.78M. Its enterprise value, which adds debt and subtracts cash, is $57.16M.

    How many shares of RANI are outstanding?

    Rani Therapeutics Holdings has 199.01M shares outstanding. The count is up 328.49% from a year earlier.

    Does RANI pay a dividend?

    No. Rani Therapeutics Holdings does not pay a dividend.

    How much debt does RANI have?

    Rani Therapeutics Holdings has $0 of total debt and $3.62M of cash and equivalents, a net cash position of $3.62M.